Intravenous Fluconazole Dosing for Candida UTI
For fluconazole-susceptible Candida urinary tract infections, administer IV fluconazole 200 mg (3 mg/kg) daily for 2 weeks for cystitis, or 200-400 mg (3-6 mg/kg) daily for 2 weeks for pyelonephritis. 1
Clinical Context and Dosing Algorithm
The IDSA 2016 guidelines provide clear, evidence-based dosing recommendations that distinguish between different types of Candida UTI:
For Candida Cystitis (Lower UTI)
- Dose: 200 mg (3 mg/kg) IV daily
- Duration: 2 weeks
- Evidence level: Strong recommendation; moderate-quality evidence 1
For Candida Pyelonephritis (Upper UTI)
- Dose: 200-400 mg (3-6 mg/kg) IV daily
- Duration: 2 weeks
- Evidence level: Strong recommendation; low-quality evidence 1
The higher dose range (400 mg) should be used for more severe pyelonephritis or when clinical response is suboptimal.
Critical Considerations Before Treatment
Remove indwelling urinary catheters whenever feasible - this is a strong recommendation that significantly impacts treatment success 1. The presence of a catheter dramatically reduces eradication rates, even with appropriate antifungal therapy 2.
When NOT to Treat
Asymptomatic candiduria does NOT require treatment unless the patient is:
- Neutropenic
- Very low-birth-weight infant (<1500g)
- Undergoing urologic manipulation 1
For these high-risk groups, treat as candidemia with higher doses.
Species-Specific Modifications
Fluconazole-Resistant Species
For C. glabrata (fluconazole-resistant):
- Amphotericin B deoxycholate 0.3-0.6 mg/kg IV daily for 1-7 days, with or without oral flucytosine 25 mg/kg four times daily 1
For C. krusei (inherently resistant):
- Amphotericin B deoxycholate 0.3-0.6 mg/kg IV daily for 1-7 days 1
Renal Dosing Adjustments
Since fluconazole is renally cleared, dose adjustment is critical 3:
- CrCl >50 mL/min: 100% of standard dose
- CrCl ≤50 mL/min (no dialysis): 50% of standard dose after loading dose
- Hemodialysis: 100% dose after each dialysis session
Always give a loading dose (50-400 mg based on indication) before adjusting for renal function 3.
Transition to Oral Therapy
The FDA label and clinical practice support transitioning to oral fluconazole once the patient can tolerate oral intake, as bioavailability is excellent (>90%) 3. The oral dose equals the IV dose, making this transition straightforward.
Duration Considerations
While guidelines recommend 14 days, recent data suggest shorter courses may be effective. A 2025 study found no difference in clinical success between 7-day and 14-day courses (93.1% vs 93.3%, P=1.000) 4. However, the guideline-recommended 14-day duration remains the standard of care until prospective trials confirm non-inferiority of shorter regimens.
Common Pitfalls to Avoid
- Don't use echinocandins for UTI - they achieve inadequate urinary concentrations 5
- Don't treat asymptomatic candiduria in low-risk patients - it often resolves spontaneously and treatment doesn't prevent complications 2
- Don't forget to eliminate urinary obstruction - this is as important as antifungal therapy 1
- Don't assume all Candida are fluconazole-susceptible - C. krusei is inherently resistant and C. glabrata frequently has reduced susceptibility 1
Pharmacokinetic Advantage
Fluconazole achieves urinary concentrations 10-20 times higher than plasma levels 6, making it ideal for UTI treatment. This explains why lower doses (200 mg) are effective for cystitis compared to systemic infections (typically 400-800 mg).